摘要
目的 分析沙库巴曲缬沙坦用于扩张型心肌病(DCM)致慢性心力衰竭(CHF)老年患者的疗效。方法 选取2020年7月至2022年7月南阳医学高等专科学校第一附属医院收治DCM致CHF老年患者总共82例,按照随机数字表法分成对照组(使用缬沙坦)、观察组(使用沙库巴曲缬沙坦)各41例,比较两组疗效;治疗前后6 min步行距离(6MWD)、N末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)、左室舒张末期内径值(LVEDD)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及超敏C反应蛋白(hs-CRP)水平;副反应出现情况。结果 观察组治疗有效率高于对照组(P <0.05)。治疗前,两组6MWD、NT-proBNP、LVEF、LVEDD、IL-6、TNF-α及hs-CRP水平相比,差异无统计学意义(P> 0.05);治疗后,两组6MWD、LVEF水平较治疗前提升,差异有统计学意义(P <0.05),NTproBNP、LVEDD、IL-6、TNF-α及hs-CRP水平较治疗前降低,差异有统计学意义(P <0.05),且观察组6MWD、LVEF水平高于对照组,差异有统计学意义(P <0.05),NT-proBNP、LVEDD、IL-6、TNF-α及hs-CRP水平低于对照组,差异有统计学意义(P <0.05)。两组低血压副反应(干咳、头晕以及血管性水肿)发生率比较,差异无统计学意义(P> 0.05)。结论 沙库巴曲缬沙坦用于DCM致CHF老年患者疗效理想,能改善其心功能,降低其炎症因子水平,同时安全性高,值得采用。
Objective To analyze the clinical efficacy of sacubitril valsartan in elderly patients with dilated cardiomyopathy(DCM)-chronic heart failure(CHF).Methods A total of 82 elderly patients with CHF caused by DCM admitted to our hospital from July 2020 to July 2022 were selected and divided into a control group(using valsartan)and an observation group(using sakubatril valsartan)of 41 cases each according to the random number table method to compare the efficacy of the two groups.Group contrast results were obtained through the curative effects,6-minute walk distance(6MWD),N-terminal pro-brain natriuretic peptide(NT-proBNP),left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),Interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),hypersensitivity C-reactive protein(hs-CRP)and adverse drug reactions.Results The effective treatment rates in the observation group were higher than control group(P<0.05).Before treatment,there were no significant between-group differences about 6MWD,NT-proBNP,LVEF,LVEDD,IL-6,TNF-αand hs-CRP values(P>0.05);after treatment,6MWD and LVEF values for two groups were significantly higher than before,the difference is statistically significant(P<0.05);NT-proBNP,LVEDD,IL-6,TNF-αand hs-CRP values for two groups were significantly lower than before,the difference is statistically significant(P<0.05);6MWD and LVEF values in the observation group were even higher than control group,the difference is statistically significant(P<0.05);NT-proBNP,LVEDD,IL-6,TNF-αand hs-CRP levels in the observation group were even lower than control group,the difference is statistically significant(P<0.05);there were no significant between-group differences about the adverse drug reactions like hypotension,dry cough,dizziness and angioedema(P>0.05).Conclusion Sacubitril valsartan can effectively reduce the inflammatory factors,improve the cardiac function and treatment safety for elderly patients with dilated cardiomyopathy-chronic heart failure.It is worthy of clinical application.
作者
张璨
王丹
ZHANG Can;WANG Dan(Cardiovascular Intensive Care Unit,the First Affiliated Hospital of Nanyang Medical College,Nanyang Henan 473000,China;Fourth Department of Psychiatry,Luoyang Fifth People’s Hospital,Luoyang Henan 471000,China)
出处
《临床研究》
2023年第6期63-66,共4页
Clinical Research
关键词
扩张型心肌病
慢性心力衰竭
沙库巴曲缬沙坦
心功能
炎症因子
dilated cardiomyopathy
chronic heart failure
sacubitril valsartan
cardiac function
inflammatory factors
